Phospholipid metabolism in health and disease
Takao Shimizu
DOI: https://doi.org/10.1254/jpssuppl.wcp2018.0_cl-31
2018-01-01
Proceedings for Annual Meeting of The Japanese Pharmacological Society
Abstract:Glycerophospholipids (phospholipids) are a major constituent of biological membrane, pulmonary surfactant lipids or precursors of bioactive lipid mediators. More than 1,000 different species in terms of fatty acid distribution, polar head groups, and linkage between glycerol backbone and fatty acyl moiety (1). Mechanism how these diversity is made, and biological output of the individual or mixed fatty acyl species remain to be fully elucidated. By molecular cloning of acyltransferases in the last decade by our group and others, we propose a new model how the diversity is made. Palmitic acid (16:0), oleic acid (18:1) and arachidonic acid (20:4) are accumulated by Lands' cycle (remodeling pathway, lysoPC to PC), while surprisingly, linoleic acid (18:2) and docosahexaenoic acid (22:6) are enriched by Kennedy pathway (Lyso-PA to PA) (2). To confirm the proposed model, we have established mice and cell lines which genetically lack one or two enzymes responsible for these reactions. We confirmed that DPPC (16:0/16:0) is produced by a Lands'enzyme, LPCAT1, which is critical for surfactant formation and pulmonary functions (2). Similarly, we found that LPCAT3, another Lands'enzyme is pivotal for formation of arachidonate-rich membrane that is related to lipoprotein formation, independent of eicosanoid synthesis (3). DHA is incorporated into phospholipid membrane in testis and retina, and loss of DHA-membrane is associated with male infertility and retinal dysfunctions (4, 5). While the molecular mechanism underlying the roles and mouse phenotypes are unclear, phospholipids with different fatty acyl species play unique and essential roles in health and disease over the just barrier functions. Supported by MEXT, AMED, and Takeda Science Foundation. The laboratory at the U-Tokyo funded by Shimadzu, Co., Ltd, and NCGM laboratory is partly supported by ONO Pharmaceutical.Ref.1. Shimizu, T. (2009) Ann. Rev. Pharmacol. Toxicol. 49, 123-150.2. Harayama, T. et al. (2014) Cell Metabolism 20, 295-3053. Hashidate-Yoshida, T. Harayama, T. et al. (2015) eLife 063284. Shindou, H. et al. (2017) J. Biol. Chem. 292, 12054-120645. Iizuka-Hishikawa, Y. et al. (2017) J. Biol. Chem. 292, 12065-12076